Commercializing the Molecular Diagnostics Market: Company Profiles, Five Year Trend Forecasts & a Detailed Market Overview

Research and Markets

Laura Wood, Senior Manager

Fax from USA: 646-607-1907

Fax from rest of the world: +353-1-481-1716

press@researchandmarkets.com

Logo: http://www.researchandmarkets.com

Research and Markets (http://www.researchandmarkets.com/research/ 8d3dd7/commercializing_mo) has announced the addition of the “Commercializing Molecular Diagnostics: Products, Services, Companies and Global Market” report to their offering.

This report is about the molecular diagnostics market, including systems, consumables and clinical lab services. These key medical products and services use technologies that can detect single or multiple genomic, protein, metabolomic or other ‘-omic’ biomarkers.

The detailed study shows that molecular diagnostic companies are expecting continued strong growth. This report shows the major areas of this dynamic market landscape, including the various views of this growing multi-billion dollar market. The study sizes the market and projects the 5-year trend. The report charts the developments of more than 80 companies involved in this dynamic industry.

This report discusses government regulatory initiatives to accelerate the approvals of emerging molecular diagnostics by integrating biomarkers and companion pharmacogenomic tests. Myriad, Veridex, Genomic Health, Agendia and others are gaining traction detecting cancers. Roche’s Affymetrix-based tests measure how patients respond to 30 or more currently marketed drugs. These products enable the emerging field of personalized medicine. The passing of the GINA law in the US might foster the growth of more molecular diagnostics, clinical lab services and other related genetic testing services.

This study is full of interesting data and includes more than 43 figures and tables. The tables provide data about technologies, companies, product pipelines, partnerships and more. The study also has additional data such as the global incidence and prevalence of major diseases. The report analyzes partnering deals and includes several years of alliance and M&A data. Thirty-eight selected companies are profiled, with details including contact information, business and product overviews, alliances and patent or other financial details.

This report would benefit people with job titles such as: CEO, VPs, Director of Business Development, Research Directors, Entrepreneurs, Venture Capitalists, Investment Planners, Research Scientists, Consultants or Industry Analysts.

Key Topics Covered:

– Molecular Diagnostics Market Landscape

– Alliances and M&As in Molecular Diagnostics

– Manufacturer Strategies

– Detection Technologies Used in Developing Molecular

– Market Size and Forecast

– Trends, Opportunities and Challenges

– Selected Molecular Diagnostic Companies

– List of Tables

– List of Illustrations

Companies Mentioned Include:

Abbott Molecular

Affymetrix, Inc.

Agendia B.V.

Asuragen, Inc.

Becton Dickinson Diagnostics

Beckman Coulter, Inc.

bioMerieux SA

BioSite, Inc. (Inverness Medical Innovations)

BML, Inc.

Chiron Corporation (Novartis)

Combimatrix Molecular Diagnostics, Inc.

Dako A/S

diaDexus, Inc.

Diagnosticos Da America S.A. (DASA)

Digene Corporation (Qiagen)

Epigenomics AG

Exact Sciences Corporation

Nanogen, Inc.

Nanosphere, Inc.

Nymox Pharmaceutical Corporation

Orion Genomics LLC

Quest Diagnostics, Inc.

Roche Molecular Diagnostics

Sequenom, Inc.

Siemens Healthcare Diagnostics (MDx business)

Sonic Healthcare Limited

Third Wave Technologies, Inc.

Unilabs Group

Veridex, LLC (J&J Co.)

For more information visit http://www.researchandmarkets.com/ research/8d3dd7/commercializing_mo

(c) 2008 BUSINESS WIRE. Provided by ProQuest Information and Learning. All rights Reserved.